House Status:
Senate Status:
Senate Status:
Minutes for SB250 - Committee on Health and Human Services
Short Title
Enacting the right to try for individualized treatments act to permit a manufacturer to make an individualized investigative treatment available to a requesting patient.
Minutes Content for Fri, Mar 7, 2025
Carly Choi provided an overview of SB250.
Ms. Choi responded to questions from the committee.
Dr. Patrick Bailey, Director of Healthcare Policy, Goldwater Institute, provided testimony in support of SB250 (Attachment 32). The bill would create a new, safe, and physician-directed pathway for patients with ultra-rare, life threatening or debilitating diseases for whom there are no other treatment options available and who could potentially benefit from an individualized treatment that is based on their unique genetic profile. Current clinical trials are designed for evaluating drugs that would be used to treat large populations. These individualized treatments are still subject to the same clinical trail process as medications intended for thousands. These advancements in genomic medicine and the innovations that provide the means to creak a bespoke medical treatment are based on one's unique DNA profile. Six states have passed similar legislation with several others considering legislation. Removing the federal bureaucratic process that hinders these treatment options requires no additional taxpayer investment.
Dr. Bailey responded to questions form the committee.
The following provided written only proponent testimony:
Elizabeth Patton, State Director, Americans for Prosperity-Kansas (Attachment 33)
Susan Gile, Executive Director, Kansas State Board of Healing Arts, provided neutral testimony for SB250 (Attachment 34). Also known as the Right to Try Act, the bill is well-intentioned. The Board does have some concerns as its fundamental mission is patient protection. While confidentiality statutes prevent from giving details, the Board currently has several cases where providers have knowingly and purportedly preyed on those with chronic pain. Remarkable results are promised that are not scientifically proven nor accepted. Concerns related to "written, informed consent" and attestation were noted to the committee. There is also concern regarding liability for expenses to the estate if death occurs during treatment.
Ms. Gile responded to questions from the committee.
The hearing was closed.
The meeting was adjourned at 3:23 PM.
